Cancers recurring after chemotherapeutic treatment often present resistances to most of the currently available anti-cancer drugs. Similar resistances also occur in the chronic treatment of infectious diseases like HIV-AIDS. Such insensitivities to therapies pose immense problems to the treatment of the affected patients. One cause of multidrug resistances is the overproduction of a membrane protein, P-glycoprotein (P-gp). This member of the ABC-transporter family pumps chemotherapeutics out of cells and thereby lowers the effective concentration to sub-therapeutic levels. More than 30 years of research geared at finding effective inhibitors of P-glycoprotein that could be used as co-therapeutics to in the treatment of patients with resistant cancers has not yielded success. In previous work, we used ultrahigh throughput computational screening of very large drug-like compound databases and a structural model of P-glycoprotein to find novel molecules that inhibit the pump and may be developed into co-therapeutics to treat chemotherapy-resistant cancers. With these techniques and subsequent biochemical and biophysical assays, we identified four compounds out of several million that indeed blocked steps in the catalytic cycle of P- glycoprotein that are necessary for drug export. Three of these compounds reversed chemotherapy resistance in multidrug resistant prostate cancer cells in culture, while showing low to no toxicity to noncancerous cells. These compounds may serve as pharmacological lead compounds for the development of co-therapeutics for therapy resistant cancer or HIV-infected patients. We propose here enhancements to our computational screening methods to increase our prediction rate and the quality of identified P-gp inhibitors. This will be accomplished by taking into account the structural changes that the pump undergoes during transport. Identified potential inhibitors will be evaluated in biochemical assays for their efficacy of blocking P-glycoprotein action. Successful candidates will then be further evaluated for their potential to reverse multidrug resistance in cancer cells and their toxicity to normal cells in culture. We further propose to develop biophysical methods that will allow us to determine the molecular mechanism that leads to inhibition of P-glycoprotein by the discovered molecules. Identified novel P-glycoprotein inhibitors from our earlier studies, as well as those discovered in the proposed studies, will be further optimized in the future for pharmaceutical use.

Public Health Relevance

Multidrug resistance phenomena remain an enormous public health problem and a major obstacle to the effective treatment of many severe human diseases. Up to ~40% of all human cancers develop multidrug resistance. These phenomena are responsible for the loss of effectiveness of many anticancer and antiviral agents and are root cause of many of the emerging antibiotic resistances of microorganisms. Even though considerable effort has been expended in the elucidation of the structure and enzymatic mechanism of the family of proteins responsible for multidrug resistance, there remain large gaps in our understanding of these important enzymes. The discovery and development of effective drugs that inhibit these enzymes and allow effective treatment of often intractable diseases like cancer or HIV infection will be of great importance. We have previously discovered four compounds that inhibited the multidrug resistance P- glycoprotein, an enzyme thought to be one of the main causes of such multidrug resistances, in biochemical assays. Three of these compounds were found to reverse chemotherapy resistance in prostate cancer cells in culture but were not significantly toxic to noncancerous cells in culture. We discovered these inhibitor compounds by using ultrahigh throughput in-silico screens of very large chemical data bases. About 10 % of the compounds tested in biochemical and biophysical assays were found to be good inhibitors. We propose in this current study to enhance the in silico selection criteria to even better predict good inhibitors of P-glycoprotein. Identified inhibitors may then be further developed as co-therapeutics in therapy of drug resistant cancers or HIV patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
2R15GM094771-02
Application #
8957587
Study Section
Macromolecular Structure and Function D Study Section (MSFD)
Program Officer
Preusch, Peter
Project Start
2011-09-05
Project End
2018-08-31
Budget Start
2015-09-15
Budget End
2018-08-31
Support Year
2
Fiscal Year
2015
Total Cost
$341,512
Indirect Cost
$101,512
Name
Southern Methodist University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
001981133
City
Dallas
State
TX
Country
United States
Zip Code
75275
Nanayakkara, Amila K; Follit, Courtney A; Chen, Gang et al. (2018) Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci Rep 8:967
Follit, Courtney A; Woodruff, Shannon R; Vogel, Pia D et al. (2017) Cationic branched polymers for cellular delivery of negatively charged cargo. J Drug Deliv Sci Technol 39:324-333
Follit, Courtney A; Brewer, Frances K; Wise, John G et al. (2015) In silico identified targeted inhibitors of P-glycoprotein overcome multidrug resistance in human cancer cells in culture. Pharmacol Res Perspect 3:e00170
McCormick, James W; Vogel, Pia D; Wise, John G (2015) Multiple Drug Transport Pathways through Human P-Glycoprotein. Biochemistry 54:4374-90
Brewer, Frances K; Follit, Courtney A; Vogel, Pia D et al. (2014) In silico screening for inhibitors of p-glycoprotein that target the nucleotide binding domains. Mol Pharmacol 86:716-26
Wise, John G (2012) Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51:5125-41